newsfilter
← Latest News
Business Wire·

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

New divesiran data continue to show substantial reduction in phlebotomy frequency and lowering of hematocrit levels in PV patients Silence also announces first subject dosed in Phase 2 study of divesiran in PV